EUVIMEDEUVIMED entdecken
Open Access

ELABELA Ameliorates Atherosclerosis Through Restoring the M1/M2 Macrophage Balance in ApoE −/− Mice

Le Tang, Xiaoli Yi, Wenting Tan, Huiru Yang, Shanshan Song, Jianhua Xiong, Chunju Liu, Yifeng Zhang iD, Mulan Wang, Mengzhi Zhu, Lixiang Zheng, Jun Yu iD und 1 weitere

Journal of the American Heart Association · 2025

DOI: 10.1161/jaha.124.041261 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Heart Association, 2025. Verfasst von Le Tang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Translational Medicine Centre Jiangxi University of Chinese Medicine Nanchang China. Hauptthemen laut MEDLINE: Atherosclerosis, Macrophages, Peptide Hormones, Aortic Diseases. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Atherosclerosis is a progressive arterial disease characterized by chronic inflammation and plaque formation in blood vessel walls. ELABELA, an endogenous ligand for the G protein‐coupled receptor APJ (apelin peptide jejunum, apelin receptor), has multiple pharmacological activities for protecting the cardiovascular system. This study aimed to determine the potential antiatherosclerotic effect of ELABELA and reveal the underlying mechanisms.

Methods

We enrolled a cohort consisting of patients with and without atherosclerosis to determine the relationship between plasma ELABELA levels and atherosclerosis severity. The potential therapeutic action of ELA‐21 (ELABELA‐21) on atherosclerosis in high‐fat diet‐fed ApoE −/− mice was evaluated.

Results

Plasma ELABELA levels were significantly reduced and negatively correlated with plasma MMP2 (matrix metallopeptidase 2) and MMP9 (matrix metallopeptidase 9) levels in patients with atherosclerosis and high‐fat diet‐induced atherosclerotic ApoE −/− mice. Plasma ELABELA levels exhibited a potential diagnostic value for patients with atherosclerosis. Applying ELA‐21 significantly decreased the atherosclerotic plaque area and inflammation in the aortas of the ApoE −/− mice. ELA‐21 administration modulated the balance between M1 and M2 macrophages in the abdominal cavity and aorta roots toward a more anti‐inflammatory status, accompanied by reduced MMP2, MMP9, and PRR ([pro]renin receptor), and enhanced macrophage APJ, ACE (angiotensin‐converting enzyme), and ACE2 (angiotensin‐converting enzyme 2) protein expression in plaques within aortic roots and decreased plasma soluble PRR levels. In vitro, ELA‐21 effectively suppressed oxidized low‐density lipoprotein‐induced foam cell formation and lipopolysaccharide/interferon‐γ‐induced M1 polarization in cultured macrophages. Interestingly, the anti‐inflammatory effect of ELA‐21 was further enhanced by APJ inhibitor ML221 [4‐oxo‐6‐((pyrimidin‐2‐ylthio)methyl)‐4H‐pyran‐3‐yl 4‐nitrobenzoate], accompanied by elevated ACE and ATP6AP2 (ATPase, H + ‐transporting, lysosomal accessory protein 2) and reduced ACE2 mRNA levels.

Conclusions

Our data highlighted the diagnostic and therapeutic potential of ELABELA on atherosclerosis. ELA‐21 protects against atherosclerosis by inhibiting atherosclerotic plaque formation and promoting a more stable plaque phenotype, possibly via restoring the M1/M2 macrophage balance, enhancing macrophage ACE and ACE2 expression, and inhibiting the PRR system. ELABELA may be a novel diagnostic biomarker and candidate therapeutic target for atherosclerosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AtherosclerosisMacrophagesPeptide HormonesAortic DiseasesAnimalsHumansMaleMiceMatrix Metalloproteinase 9Disease Models, AnimalMatrix Metalloproteinase 2Mice, Knockout, ApoEPlaque, AtheroscleroticApolipoproteins EFemaleMice, Inbred C57BLAortaMiddle Aged

Stichwörter der Autor:innen

ELABELAatherosclerosismacrophagerenin‐angiotensin system

Substanzen

Matrix Metalloproteinase 9Matrix Metalloproteinase 2Peptide HormonesAPELA protein, humanApolipoproteins EMmp2 protein, mouseMmp9 protein, mouse

Autor:innen und Institutionen

  • Translational Medicine Centre Jiangxi University of Chinese Medicine Nanchang China.
  • Center for Metabolic Disease Research and Department of Cardiovascular Sciences, Lewis Katz School of Medicine Temple University Philadelphia PA USA.
  • Department of Cardiology Affiliated Hospital of Jiangxi University of Chinese Medicine Nanchang China.
  • Department of Clinical Laboratory Affiliated Hospital of Jiangxi University of Chinese Medicine Nanchang China.
  • College of Traditional Chinese Medicine, Jiangxi University of Chinese Medicine Nanchang China.

ORCID-Profile: Yifeng Zhang, Jun Yu, Chuanming Xu

Zitieren

APA

Tang, L., Yi, X., Tan, W., Yang, H., Song, S., Xiong, J., Liu, C., Zhang, Y., Wang, M., Zhu, M., Zheng, L., Yu, J., & Xu, C. (2025). ELABELA Ameliorates Atherosclerosis Through Restoring the M1/M2 Macrophage Balance in ApoE −/− Mice. Journal of the American Heart Association. https://doi.org/10.1161/jaha.124.041261

Vancouver

Tang L, Yi X, Tan W, Yang H, Song S, Xiong J, et al. ELABELA Ameliorates Atherosclerosis Through Restoring the M1/M2 Macrophage Balance in ApoE −/− Mice. Journal of the American Heart Association. 2025. doi:10.1161/jaha.124.041261

BibTeX
@article{Tang2025,
  author = {Tang, Le and Yi, Xiaoli and Tan, Wenting and Yang, Huiru and Song, Shanshan and Xiong, Jianhua and Liu, Chunju and Zhang, Yifeng and Wang, Mulan and Zhu, Mengzhi and Zheng, Lixiang and Yu, Jun and Xu, Chuanming},
  title = {ELABELA Ameliorates Atherosclerosis Through Restoring the M1/M2 Macrophage Balance in ApoE −/− Mice},
  journal = {Journal of the American Heart Association},
  year = {2025},
  doi = {10.1161/jaha.124.041261}
}
Kostenlos starten →